ECMO与非ECMO急性呼吸窘迫综合征存活者队列的功能恢复
该多中心回顾性队列纳入110例至随访门诊就诊的ARDS存活者,其中34例接受ECMO治疗。ECMO组更年轻(35 vs 51岁,p<0.01)、COVID-19比例更低(58% vs 96%,p<0.01),但SOFA评分更高(7 vs 4,p<0.01)、动态肺顺应性更低(15 vs 27 mL/cmH20,p<0.01)、氧合指数更高(26 vs 9,p<0.01),且住院时间、ICU停留时间和机械通气时间均显著更长(均p<0.01)。主要终点FVC%预计值及其他肺、神经认知或精神功能恢复标志物在两组间相似;校正年龄、SOFA、COVID-19状态或住院时间后,ECMO未预测肺功能变化。
要点
- 在110例ARDS存活者中,ECMO组(34例)与非ECMO组的FVC%预计值及其他功能恢复结局无显著差异。
- ECMO组更年轻(35 vs 51岁,p<0.01)、COVID-19比例更低(58% vs 96%,p<0.01),但SOFA更高(7 vs 4,p<0.01)。
- ECMO组动态肺顺应性更低(15 vs 27 mL/cmH20,p<0.01)、氧合指数更高(26 vs 9,p<0.01),且更多需要挽救性通气模式。
- ECMO组住院时间(46 vs 16天,p<0.01)、ICU停留时间(29 vs 10天,p<0.01)和机械通气时间(24 vs 10天,p<0.01)均显著更长。
- 校正年龄、SOFA、COVID-19状态或住院时间后,ECMO未预测肺功能变化。
适用人群与场景
- 至随访门诊就诊的ARDS存活者,共110例,其中34例接受ECMO治疗。
研究设计与关键结果
- 多中心回顾性队列研究纳入110例ARDS存活者,ECMO组34例;主要终点为FVC%预计值。
- ECMO组年龄35(28,50)岁 vs 非ECMO组51(44,61)岁,p<0.01;COVID-19比例58% vs 96%,p<0.01。
- ECMO组SOFA评分7(5,9) vs 4(3,6),p<0.01;动态肺顺应性15(11,20) mL/cmH20 vs 27(23,35) mL/cmH20,p<0.01;氧合指数26(22,33) vs 9(6,11),p<0.01。
- ECMO组住院时间46(27,62)天 vs 16(12,31)天,p<0.01;ICU停留时间29(19,43)天 vs 10(5,17)天,p<0.01;机械通气时间24(14,42)天 vs 10(7,17)天,p<0.01。
- ECMO与非ECMO患者的FVC%预计值及其他肺、神经认知或精神功能恢复结局相似;校正年龄、SOFA、COVID-19状态或住院时间后,ECMO未预测肺功能变化。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The mortality benefit of VV-ECMO in ARDS has been extensively studied, but the impact on long-term functional outcomes of survivors is poorly defined. We aimed to assess the association between ECMO and functional outcomes in a contemporaneous cohort of survivors of ARDS.
METHODS: Multicenter retrospective cohort study of ARDS survivors who presented to follow-up clinic. The primary outcome was FVC% predicted. Univariate and multivariate regression models were used to evaluate the impact of ECMO on the primary outcome.
RESULTS: This study enrolled 110 survivors of ARDS, 34 of whom were managed using ECMO. The ECMO cohort was younger (35 [28, 50] vs. 51 [44, 61] years old, p < 0.01), less likely to have COVID-19 (58% vs. 96%, p < 0.01), more severely ill based on the Sequential Organ Failure Assessment (SOFA) score (7 [5, 9] vs. 4 [3, 6], p < 0.01), dynamic lung compliance (15 mL/cmH20 [11, 20] vs. 27 mL/cmH20 [23, 35], p < 0.01), oxygenation index (26 [22, 33] vs. 9 [6, 11], p < 0.01), and their need for rescue modes of ventilation. ECMO patients had significantly longer lengths of hospitalization (46 [27, 62] vs. 16 [12, 31] days, p < 0.01) ICU stay (29 [19, 43] vs. 10 [5, 17] days, p < 0.01), and duration of mechanical ventilation (24 [14, 42] vs. 10 [7, 17] days, p < 0.01). Functional outcomes were similar in ECMO and non-ECMO patients. ECMO did not predict changes in lung function when adjusting for age, SOFA, COVID-19 status, or length of hospitalization.
CONCLUSIONS: There were no significant differences in the FVC% predicted, or other markers of pulmonary, neurocognitive, or psychiatric functional recovery outcomes, when comparing a contemporaneous clinic-based cohort of survivors of ARDS managed with ECMO to those without ECMO.
参考来源
- Snyder M, Njie BY, Grabenstein I, et al. Functional recovery in a cohort of ECMO and non-ECMO acute respiratory distress syndrome survivors. Crit Care. 2023. PMID: 37964311. doi:10.1186/s13054-023-04724-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。